✦ LIBER ✦
Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non–Small-Cell Lung Cancer
✍ Scribed by David R. Spigel; Martin J. Edelman; Tony Mok; Kenneth O'Byrne; Luis Paz-Ares; Wei Yu; Karen Rittweger; Holger Thurm
- Book ID
- 119218698
- Publisher
- CIG Media Group, LP.
- Year
- 2012
- Tongue
- English
- Weight
- 255 KB
- Volume
- 13
- Category
- Article
- ISSN
- 1525-7304
No coin nor oath required. For personal study only.